Advancements in Glioma Treatment: How can Clinical Outcomes be Optimized?

2024 Neuro-Oncology Update: Brain Tumors

By Scripps Health FEATURING Tresa McGranahan

1,099 views

April 2, 2024

Disclaimer: On August 6, 2024, the FDA approved vorasidenib (Voranigo) for adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following surgery including biopsy, sub-total resection, or gross total resection.

Comments 1